克唑替尼治疗间变性淋巴瘤激酶重排的炎性肌纤维母细胞瘤。
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
机构信息
Dana-Farber Cancer Institute, Boston, MA 02115, USA.
出版信息
N Engl J Med. 2010 Oct 28;363(18):1727-33. doi: 10.1056/NEJMoa1007056.
Abstract
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
摘要
炎性肌纤维母细胞瘤（IMT）是一种独特的间叶性肿瘤，其特征为梭形细胞增生伴炎症浸润。大约一半的 IMT 存在染色体 2p23 上的间变性淋巴瘤激酶（ALK）基因重排，导致异常的 ALK 表达。我们报告了一例 ALK 易位 IMT 患者对 ALK 抑制剂克唑替尼（PF-02341066，辉瑞）的持续部分缓解，而另一例无 ALK 易位的患者则未观察到活性。这些结果支持 ALK 重排肿瘤对 ALK 介导的信号的依赖性，并为这种软组织肿瘤侵袭性形式的基因组鉴定患者提供了一种治疗策略。（由辉瑞等资助；ClinicalTrials.gov 编号，NCT00585195.）。
相似文献
1
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.克唑替尼治疗间变性淋巴瘤激酶重排的炎性肌纤维母细胞瘤。
N Engl J Med. 2010 Oct 28;363(18):1727-33. doi: 10.1056/NEJMoa1007056.
2
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
3
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.克唑替尼治疗儿童难治性实体瘤或间变大细胞淋巴瘤的安全性和活性：儿童肿瘤学组 1 期联盟研究。
Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.
4
Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.新辅助克唑替尼治疗ALK基因重排的晚期炎性肌纤维母细胞瘤
Tumori. 2015 Apr 28;101(2):e35-9. doi: 10.5301/tj.5000245.
5
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.克唑替尼，一种c-Met和ALK受体酪氨酸激酶的小分子双重抑制剂。
Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90.
6
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.神经母细胞瘤相关的 F1174L ALK 突变导致 ALK 易位癌症对 ALK 激酶抑制剂产生耐药性。
Cancer Res. 2010 Dec 15;70(24):10038-43. doi: 10.1158/0008-5472.CAN-10-2956. Epub 2010 Oct 28.
7
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.
8
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.克唑替尼：一种新型的、同类首创的多靶点酪氨酸激酶抑制剂，用于治疗间变性淋巴瘤激酶重排的非小细胞肺癌及其他疾病。
Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23.
9
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.克唑替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌：分子靶向治疗在肿瘤学中开启第二个十年的成功典范。
Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18.
10
Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.炎性肌纤维母细胞瘤含有多种潜在可靶向的激酶融合。
Cancer Discov. 2014 Aug;4(8):889-95. doi: 10.1158/2159-8290.CD-14-0377. Epub 2014 May 29.
引用本文的文献
1
CD20-Negative Large B-Cell Lymphomas: The Diagnostic Challenge of Tumors with Downregulation of Mature B-Cell Marker Expression.CD20阴性大B细胞淋巴瘤：成熟B细胞标志物表达下调肿瘤的诊断挑战
Int J Mol Sci. 2025 Aug 14;26(16):7843. doi: 10.3390/ijms26167843.
2
A Case of Inflammatory Myofibroblastic Tumor in the Abdominal Wall with Anaplastic Lymphoma Kinase and Whole Exome Sequencing Analysis.腹壁炎性肌纤维母细胞瘤伴间变性淋巴瘤激酶及全外显子测序分析1例
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0181. Epub 2025 Jul 16.
3
TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature.TFCP2融合阳性横纹肌肉瘤：10例报告及文献复习
Cancers (Basel). 2025 Apr 25;17(9):1441. doi: 10.3390/cancers17091441.
4
Novel Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report.转移性炎性肌纤维母细胞瘤中克唑替尼耐药的新型双重融合机制：一例报告
JTO Clin Res Rep. 2025 Jan 7;6(5):100791. doi: 10.1016/j.jtocrr.2025.100791. eCollection 2025 May.
5
Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis.ALK高表达在小细胞肺癌中的预后意义：一项9年队列分析
Front Oncol. 2025 Mar 25;15:1530339. doi: 10.3389/fonc.2025.1530339. eCollection 2025.
6
Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.携带复杂罕见ALK融合的胸内炎性肌纤维母细胞瘤对劳拉替尼部分缓解：一例报告
Transl Lung Cancer Res. 2025 Feb 28;14(2):631-638. doi: 10.21037/tlcr-24-963. Epub 2025 Feb 27.
7
Successful management of an unusual case of pediatric inflammatory myofibroblastic tumor: a case report and literature review.小儿炎性肌纤维母细胞瘤罕见病例的成功管理：一例报告及文献综述
Ann Med Surg (Lond). 2025 Jan 9;87(1):407-412. doi: 10.1097/MS9.0000000000002870. eCollection 2025 Jan.
8
Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor.《中国炎性肌纤维母细胞瘤诊断与治疗专家共识》
Thorac Cancer. 2025 Mar;16(5):e70027. doi: 10.1111/1759-7714.70027.
9
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶：从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
10
Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response.病例报告：序贯使用ALK酪氨酸激酶抑制剂治疗的肌肉骨骼转移性炎性肌纤维母细胞瘤（IMT）并获得长期缓解
Front Oncol. 2025 Jan 27;14:1505257. doi: 10.3389/fonc.2024.1505257. eCollection 2024.
本文引用的文献
1
Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.上皮样炎性肌纤维母细胞肉瘤：一种具有核膜或核周 ALK 的侵袭性腹腔内炎性肌纤维母细胞瘤变体。
Am J Surg Pathol. 2011 Jan;35(1):135-44. doi: 10.1097/PAS.0b013e318200cfd5.
2
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
3
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
4
Anaplastic lymphoma kinase: signalling in development and disease.间变性淋巴瘤激酶：发育与疾病中的信号传导
Biochem J. 2009 May 27;420(3):345-61. doi: 10.1042/BJ20090387.
5
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.间变性淋巴瘤激酶：在癌症发病机制中的作用及用于治疗的小分子抑制剂研发
Expert Rev Anticancer Ther. 2009 Mar;9(3):331-56. doi: 10.1586/14737140.9.3.331.
6
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.非小细胞肺癌中对表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的机制
Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248.
7
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.PF-2341066（一种间变性淋巴瘤激酶和c-Met的新型抑制剂）在间变性大细胞淋巴瘤实验模型中的减瘤抗肿瘤活性。
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22. doi: 10.1158/1535-7163.MCT-07-0365.
8
Inflammatory myofibroblastic tumours: where are we now?炎性肌纤维母细胞瘤：我们目前的进展如何？
J Clin Pathol. 2008 Apr;61(4):428-37. doi: 10.1136/jcp.2007.049387. Epub 2007 Oct 15.
9
Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy.小儿膀胱炎性肌纤维母细胞瘤术前抗炎治疗成功
Urology. 2007 Aug;70(2):372.e13-5. doi: 10.1016/j.urology.2007.04.047.
10
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.开发用于TPM3-ALK诱导肿瘤发生的条件性生物发光移植模型，作为验证ALK依赖性癌症靶向治疗的工具。
Cancer Biol Ther. 2007 Aug;6(8):1318-23. doi: 10.4161/cbt.6.8.4508. Epub 2007 May 29.
Zotero 插件